Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study
Authors:
- 1 September 2015
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 2 (9) , e376-e384
Abstract
No abstract availableKeywords
Funding Information
- Bill & Melinda Gates Foundation
- Bill & Melinda Gates Foundation
- Global Fund to Fight HIV, Tuberculosis and Malaria
- US PEPFAR
- Government of Rwanda
This publication has 35 references indexed in Scilit:
- When to start antiretroviral therapy: the need for an evidence base during early HIV infectionBMC Medicine, 2013
- When to Start ART in Africa — An Urgent Research PriorityNew England Journal of Medicine, 2013
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Use of routine data collected by the prevention of mother-to-child transmission program for HIV surveillance among pregnant women in Rwanda: opportunities and limitationsAIDS Care, 2011
- Trends in the clinical characteristics of HIV‐infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009Journal of the International AIDS Society, 2011
- Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South AfricaAIDS, 2010
- Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmesThe Lancet, 2010
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalNew England Journal of Medicine, 2009
- Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe Lancet, 2009
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994